Hypogammaglobulinemia Following Use of An Anti-neonatal Fc Receptor (FcRn) Monoclonal Antibody, Efgartigimod.

Efgartigimod, an anti-neonatal Fc receptor (FcRn) monoclonal antibody recently approved for IgG-mediated autoimmune diseases, such as myasthenia gravis, accelerates IgG destruction via FcRn inhibition. Due to recent FDA approval of efgartigimod, data regarding the risk of hypogammaglobulinemia and infections in patients receiving efgartigimod is limited.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research